Evidence map›Paper›PMID 40528239›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.

Kang Xu, Hao Chen, Xingyu Zhu, Han Li, Xinyu Liu, Yaodong Sang, Xiaohan Wang, Xiaoling Cui, Baoshan Cai, Liang Shang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kang Xu *Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Hao Chen *Clinical Research Center of Shandong University, Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, 250000, China.
Xingyu Zhu *Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Han Li *Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250000, China.
Xinyu LiuDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Yaodong SangDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Xiaohan WangDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Xiaoling CuiDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Baoshan CaiDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Liang ShangDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China. docshang@163.com.
Wei ChongDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China. chongwei.good@163.com.ORCID http://orcid.org/0000-0002-1074-8595
Leping LiDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China. lileping@medmail.com.cn.

Funding

Key Technology Research and Development Program of Shandong Province No.2021CXGC011104National Natural Science Foundation of China 82372772National Natural Science Foundation of China 82473112Natural Science Foundation of Shandong Province of China ZR2024MH011Special Foundation for Taishan Scholars Program of Shandong Province No. tsqn202306373Youth Innovation Science and Technology Program of Shandong Provincial Universities 2022KJ187Youth Innovation Science and Technology Program of Shandong Provincial Universities 2023KJ018
6 · The paper itself

Abstract

Diffuse-type gastric cancer (DGC) accounts for approximately one-third of gastric cancer cases, but it is clinically more aggressive and associated with poorer survival prognosis compared to intestinal-type gastric cancer (IGC). Our study revealed significantly reduced ESRP1 expression in DGC patients relative to IGC counterparts, with its high expression positively correlating with DGC patient prognosis. Both in vitro and in vivo experimental models demonstrated that ESRP1 has the ability to hinder the malignant progression of DGC. Mechanistically, ESRP1 interacts with DHCR7, a ferroptosis-promoting regulator, thereby upregulating DHCR7 expression and enhancing ferroptosis susceptibility in DGC cells. In DGC patients with high ESRP1 expression, ferroptosis-inducing therapy emerges as a promising treatment alternative. Moreover, for ESRP1-low DGC cases, we identified several potent small-molecule drugs. These findings collectively position ESRP1 as a potential therapeutic target for DGC intervention.

Indexed as

FerroptosisRNA-Binding ProteinsStomach NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMicePrognosisXenograft Model Antitumor AssaysRNA-Binding ProteinsDiffuse-type gastric cancerEpithelial splicing regulatory protein 1FerroptosisMetabolismTherapeutic targetTumor mutational burden

Identifiers

PMID40528239
PMCPMC12175430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.